Simile raises $200 million Series B at $2 billion valuation

Simile announced a $200 million Series B on July 30, pushing its post‑money valuation to $2 billion—just five months after a $100 million Series A—underscoring rapid investor confidence in its agentic twin technology for market research [2].

Funding details and investor lineup

The round was spearheaded by Greenoaks, with existing backers Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition and CVS Health Ventures also participating [2][4]. Simile’s disclosed total funding now exceeds $300 million, reflecting a five‑fold revenue jump and a headcount of more than 50 employees since its public debut [4]. The company plans to use the capital to expand model training, compute infrastructure, and commercial teams, as well as to develop a “first‑of‑its‑kind” confidence model that predicts the accuracy of each simulation [2].

Market positioning and product outlook

Simile’s core offering—AI‑driven “agentic twins” that emulate human decision‑making—targets enterprises seeking real‑time consumer insights. Unlike traditional survey panels, these digital personas can run millions of simulations in seconds, allowing brands to test pricing, messaging, and product features instantly. The startup claims its platform has already run tens of millions of simulations for Fortune 100 firms, and it aims to broaden its persona library across healthcare, finance, consumer products and media [4]. Analysts note that while the technology promises faster, cheaper research, it also raises concerns about data privacy, bias replication, and the need for auditability, which could invite regulatory scrutiny [2].

What to watch

• Funding milestones: Follow any subsequent financing rounds that could further inflate valuation or dilute existing stakes.
• Product roll‑outs: Monitor the launch of the confidence‑score model, which may become a benchmark for synthetic‑user reliability.
• Regulatory signals: Watch for emerging guidelines on behavioral AI and data linkage, especially given CVS Health’s pilot use of the platform [2].

Simile’s swift ascent to unicorn status highlights the growing appetite for AI that predicts behavior rather than merely generates content, but the path forward will hinge on how the firm addresses privacy and bias challenges while scaling its simulations.